Quick Answer
MapLight Therapeutics, Inc. reported R&D Expense of $138.35 million for fiscal year 2025.
MapLight Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $138.35M | +101.9% |
| 2024 | $68.52M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $27.09M | +61.1% | +61.1% |
| September 30, 2024 | $16.81M | — | — |
- MapLight Therapeutics, Inc. showed an increase of +101.9% in R&D Expense compared to the prior fiscal year.
- Over the 2024–2025 period, MapLight Therapeutics, Inc.’s r&d expense has grown by 101.9% (from $68.52 million to $138.35 million).
- The most recent figure is from MapLight Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: